This document discusses oncolytic viruses, which are viruses that can selectively target and kill cancer cells. It covers the mechanisms of oncolytic viruses, factors to consider in their development like size and pathogenicity, and different families of oncolytic viruses. Specific oncolytic viruses discussed include herpes simplex virus, T-VEC, HF10, and vaccinia virus. The document also examines combination therapies using oncolytic viruses and biomarkers for assessing their delivery and activity in tumor immunotherapy.

1. The Development of Oncolytic Viruses

2. Mechanism of Oncolytic Viruses

3. Mechanism of Oncolytic Viruses

4. Main Factors to be Considered in the Development of OV

5. Oncolytic Virus Families and Characteristics

6. Criteria for the selection of oncolytic
The viral genome
Size of the virus
Pathogenicity of the virus
Immunogenicity of the virus
Penetration of the central nervous system
Mechanism of cell entry
Stability of the virus
Prime–boost strategies

7. Oncolytic Virus Combination Therapy

8. The effects of immunotherapies on the cancer–immunity cycle

9. Immunostimulatory transgenes encoded by oncolytic viruses
Combination with cytokines

10. Methods of oncolytic virus delivery in tumor immunotherapy

11. Biomarkers to assess pharmacodynamic activity
Delivery
Cytotoxicity biomarkers
Tumor microenvironment remodeling biomarkers

12. Representative Oncolytic Viruses
Herpes Simplex Virus
T-VEC
HF10
Vaccinia virus
JX-594

13. Structure of Herpes Simplex Virus-1

14. oHSVs of genetic engineering and its clinical application
Oncolytic Herpes Simplex Virus

15. Modifications Involved in the Genome of T-VEC

16. Oncolytic Virus Immunotherapy
Herpes Simplex Virus
T-VEC
approved in the US in October 2015

17. The Clinic Use of T-VEC

18. Modifications Involved in the Genome of HF-10

19. Structure of Herpes Simplex Virus-1

20. Modifications Involved in the Genome of Pexa-Vac

21. Mechanism of Pexa-Vac

22. Thanks!